SCHEMBL41794

SCHEMBL41794

CC(=O)Nc1nc(C)c(S(N)(=O)=O)s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 12/20 0.59
PIK3CA P42336 8/20 0.59
PIK3CD O00329 7/20 0.59
PIK3CB P42338 7/20 0.59
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
CA12 O43570 1/20 0.54
CA11 O75493 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA3 P07451 1/20 0.54
THRB P10828 1/20 0.54
CA4 P22748 1/20 0.54
CA6 P23280 1/20 0.54
CA5A P35218 1/20 0.54
CA7 P43166 1/20 0.54
BLM P54132 1/20 0.54
CA9 Q16790 1/20 0.54
CA13 Q8N1Q1 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4854398 0.86 PIK3CG (0.50) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
SCHEMBL10125972 0.86 PIK3CG (0.57) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
Hydrochloric Acid SCHEMBL28106590 0.85 RORA (0.49) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
SCHEMBL14269496 0.85 RORA (0.49) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
SCHEMBL241490 0.85 RORA (0.49) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
SCHEMBL14194329 0.85 RORA (0.49) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
SCHEMBL5449950 0.85 RORA (0.49) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
SCHEMBL12197706 0.83 RORA (0.54) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
SCHEMBL2346078 0.83 CA2 (0.54) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
SCHEMBL2027801 0.82 RORA (0.47) PIK3CGPIK3CAPIK3CDPIK3CBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260056191-A1 POLYMERS AND CONJUGATES COMPRISING THE SAME VENTANA MEDICAL SYSTEMS, INC. (US) 2026-02-26 US claimed
US-20240123045-A1 NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS BRENUS PHARMA (FR) 2024-04-18 US claimed
EP-4297874-A1 NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS BRENUS PHARMA (FR) 2024-01-03 EP claimed
WO-2022180251-A1 NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS BRENUS PHARMA (FR) 2022-09-01 WO claimed
US-11079372-B2 Polymers and conjugates comprising the same VENTANA MEDICAL SYSTEMS, INC. (US) 2021-08-03 US claimed
US-10775281-B2 Polymer stabilization of chromogen solutions VENTANA MEDICAL SYSTEMS, INC. (US) 2020-09-15 US claimed
EP-3276349-B1 HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE VENTANA MED SYST INC (US) 2019-08-07 EP claimed
EP-2686438-B1 A METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFOR VENTANA MED SYST INC (US) 2018-04-18 EP claimed
EP-3276349-A1 HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE Ventana Medical Systems, Inc. (US) 2018-01-31 EP claimed
EP-3201628-A2 POLYMERS AND CONJUGATES COMPRISING THE SAME Ventana Medical Systems, Inc. (US) 2017-08-09 EP claimed
EP-3029461-A1 HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE Ventana Medical Systems, Inc. (US) 2016-06-08 EP claimed
WO-2016050913-A2 POLYMERS AND CONJUGATES COMPRISING THE SAME VENTANA MEDICAL SYSTEMS, INC. (US) 2016-04-07 WO claimed
EP-2686438-A1 A METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFORE Ventana Medical Systems, Inc. (US) 2014-01-22 EP claimed
CN-103534359-A A method of analyzing chromosomal translocations and a system therefore VENTANA MED SYST INC 2014-01-22 CN claimed
EP-2539466-A1 CYTOGENIC ANALYSIS OF METAPHASE CHROMOSOMES Ventana Medical Systems, Inc. (US) 2013-01-02 EP claimed
EP-2539355-A1 POLYTAG PROBES Ventana Medical Systems, Inc. (US) 2013-01-02 EP claimed
US-20120301886-A1 POLYTAG PROBES VENTANA MEDICAL SYSTEMS, INC. 2012-11-29 US claimed
US-20120301885-A1 CYTOGENIC ANALYSIS OF METAPHASE CHROMOSOMES TANG LEI (US) 2012-11-29 US claimed
US-20120237930-A1 METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFORE VENTANA MEDICAL SYSTEMS, INC. 2012-09-20 US claimed
WO-2012123387-A1 A METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFORE F. HOFFMANN-LA ROCHE AG (CH) 2012-09-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260056191-A1 POLYMERS AND CONJUGATES COMPRISING THE SAME POLD1, POLL, INCENP PIK3CG 1599/4885PIK3CA 601/4885PIK3CD 798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.